EC Number   |
Natural Substrates |
|---|
    1.1.1.213 | 10-oxonortriptyline + NADPH |
a drug acting as substrate |
| 1.1.1.213 | 17beta-hydroxy-5alpha-androstan-3-one + NAD(P)H + H+ |
- |
| 1.1.1.213 | 17beta-hydroxy-5alpha-androstan-3-one + NAD(P)H + H+ |
termination of androgen action |
| 1.1.1.213 | 17beta-hydroxy-5alpha-androstan-3-one + NAD(P)H + H+ |
conversion in animal tissues |
| 1.1.1.213 | 17beta-hydroxy-5alpha-androstan-3-one + NAD(P)H + H+ |
regulation of the amount of androgen in prostate, high levels of substrate are required for normal and abnormal growth of prostate |
| 1.1.1.213 | 2 tibolone + 2 NADPH + 2 H+ |
i.e. tibolone, a 3-ketosteroid androgen receptor, conversion to potent estrogen receptor alpha agonists, tibolone induces estrogen receptor alpha-dependent gene promoter activity through cis-acting estrogen response elements, increases the stimulatory effect of TGF-beta on Smad-dependent gene promoter activity, and enhances prostaglandin E2-induced activity of transcription factor Runx2, overview |
| 1.1.1.213 | 3-ketosteroids + NADPH |
- |
| 1.1.1.213 | 3alpha,5alpha-allopregnenolone + NAD(P)+ |
i.e. 3alpha,5alpha-tetrahydroprogesterone or 3alpha,5alpha-THP, the enzyme catalyzes the biosynthesis and oxidation of 3alpha,5alpha-reduced neurosteroids as allopregnanolone, which stimulates GABAA receptors, sciatic nerves-induced analgesia results in increased enzyme levels in neuropathic rats, overview |
| 1.1.1.213 | 3alpha-androstanediol + NAD+ |
steroid reduction direction is preferred |
| 1.1.1.213 | 4-acetylpyridine + NADPH + H+ |
- |
